Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Delivers On Generic Fostair With UK Luforbec Launch

UK’s NHS Spends Around $250m Per Year On Asthma And COPD Treatment

Executive Summary

Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.

You may also be interested in...



Phargentis Gets European Partner For Fostair Rival

Swiss respiratory specialist Phargentis has struck a deal with “one of Europe’s leading generic pharma companies” for commercial rights to its proposed rival to Chiesi’s Fostair (beclomethasone/formoterol) respiratory brand.

Lupin Lines Up A Pair Of US Launches

India’s Lupin has launched its droxidopa rival to Northera in the US, in 100mg, 200mg and 300mg strengths. The company also launched the generic version of Horizon’s Duexis ibuprofen/famotidine 800mg/26.6mg tablets.

Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta

Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel